---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-326119"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2026-07-30T20:09:36+00:00"
generated_at: "2026-07-30T20:11:47.762002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q2 2026 revenue $85.4M, GAAP loss $1.05/share, revises FY revenue guidance to $330-340M

## Summary
- Revenue of $85.4M, up 20.1% sequentially; GAAP gross margin 30.1%.
- GAAP net loss $29.5M ($1.05 loss per share); non-GAAP loss $16.2M ($0.58 loss per share).
- Repurchased 1.5M shares for $23.8M in Q2 2026.
- Cash and investments $551.5M plus anticipated tax refund of ~$106.1M.
- Revised annual revenue guidance to $330-340M from prior range (not disclosed).

## SEC filing metadata
- accession: 0001193125-26-326119
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2026-07-30T20:09:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/0001193125-26-326119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-326119
- JSON: https://secwatch.observer/filing/0001193125-26-326119.json
- Plain text: https://secwatch.observer/filing/0001193125-26-326119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.